1
|
Boyko AN. Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119:86-93. [DOI: 10.17116/jnevro20191192286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
2
|
Ragonese P, Aridon P, Vazzoler G, Mazzola MA, Lo Re V, Lo Re M, Realmuto S, Alessi S, D’Amelio M, Savettieri G, Salemi G. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study. BMC Neurol 2017; 17:155. [PMID: 28789625 PMCID: PMC5549380 DOI: 10.1186/s12883-017-0932-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 07/31/2017] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. METHODS We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general population of Sicily in similar age groups. RESULTS On an overall cohort of 531 MS patients (346 women and 185 men) exposed to IS, we estimated a crude incidence rate for cancer of 2.26% (2.02% in women, 2.7% in men). Cancer risk was higher compared to rates observed among an equal number of patients not exposed to IS, and to the risk in the general population in Sicily at similar age groups (adjusted HR: 11.05; CI 1.67-73.3; p = 0.013). CONCLUSION The present study showed a higher cancer risk in MS patients associated only to previous IS exposure. Studies on long-term outcomes are essential to evaluate the possibility that treatment options that need to be considered for a long time-period may modify risk for life threatening diseases.
Collapse
Affiliation(s)
- Paolo Ragonese
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Paolo Aridon
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Giulia Vazzoler
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Maria Antonietta Mazzola
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Vincenzina Lo Re
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Marianna Lo Re
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Sabrina Realmuto
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Simona Alessi
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Marco D’Amelio
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Giovanni Savettieri
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| | - Giuseppe Salemi
- Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche (Department of Experimental Biomedicine and Clinical Neurosciences), Università degli Studi di Palermo, Via G. La Loggia, 1, 90129 Palermo, Italy
| |
Collapse
|